HiFiBiO Therapeutics and Leading Academic Institutions Demonstrate Breakthrough Single-Cell Approach for Novel Biomarker Discovery to Combat Cancer

New Nature Genetics publication describes novel high-throughput
single-cell ChIP-seq approach to studying heterogeneity of chromatin
states within complex biological systems

CAMBRIDGE, Mass. & PARIS & SHANGHAI & HONG KONG–(BUSINESS WIRE)–#biotherapeutics—HiFiBiO
Therapeutics, a pioneer in innovative biotherapeutics with a unique
single-cell analytics platform for extensive immune profiling, today
announced results from a breakthrough translational study in
collaboration with scientists at world-leading academic institutions. A
manuscript, “High-Throughput
Single-Cell ChIP-seq Identifies Heterogeneity of Chromatin States in
Breast Cancer,” was released online ahead of publication in
Nature Genetics.

In this study, scientists from HiFiBiO Therapeutics, ESPCI Paris and the
Institut Curie applied HiFiBiO Therapeutics’ proprietary single-cell
CelliGO™ platform and unique Drug Intelligent Science (DIS™)
capabilities to probe why certain disease cells are resistant to
available therapeutics. The team demonstrated a novel high-throughput
single-cell ChIP-seq (scChIP-seq) approach that overcomes the current
limitations of chromatin immunoprecipitation followed by sequencing
(ChIP-seq) technologies to better understand the role chromatin
heterogeneity plays in cellular differentiation and development. The
team used the scChIP-seq approach to discover new biomarkers for triple
negative breast cancer, which led to several patent applications.

“This publication is a major milestone for HiFiBiO Therapeutics and
another example of how we are applying our proprietary single-cell
technology platform to develop new solutions that can address unmet
medical needs and transform patient care,” said Liang Schweizer, PhD,
CEO and President of HiFiBiO Therapeutics. “The new HiFiBiO scChIP-seq
approach enables us and our collaborators to target more precise patient
subsets and generate higher and longer lasting responses to the
innovative therapeutics under development.”

The new scChIP-seq approach profiles chromatin landscapes of thousands
of cells in tumors and other complex biological systems with high
accuracy at single-cell resolution. Using patient-derived xenograft
models of acquired resistance to chemotherapy and targeted therapy for
triple negative breast cancer patients, the team identified a subset of
cells within the untreated drug-sensitive tumors that share a common
chromatin signature with resistant cells, undetectable by using bulk
approaches. This signature has the potential to lead to the discovery of
new drug targets and biomarkers for patient stratification.

“We are committed to partnering with leading academic institutions, as
well as pharmaceutical and biotechnology companies. We strongly believe
that our proprietary CelliGO platform and unique DIS capabilities
can accelerate the development of high-quality antibody drugs and enable
novel biomarker discovery for better patient stratification and clinical
success,” said Annabelle Gérard, PhD, Senior author of the publication
and Head of External Innovation at HiFiBiO Therapeutics. “Together with
scientists at ESPCI Paris and the Institut Curie, we have demonstrated a
new approach that enables the scientific community to decipher novel
biology, understand mechanisms of action, develop more effective
therapeutics, and design targeted clinical trials for patients with
cancer and other complex diseases.”

To read the full manuscript, please visit https://www.nature.com/articles/s41588-019-0424-9.

About HiFiBiO Therapeutics

HiFiBiO Therapeutics is an emerging multinational biotherapeutics
company mobilizing the human immune system to combat disease. The
company integrates deep-rooted biological expertise with its
comprehensive single-cell profiling technologies to discover and
accelerate a pipeline of antibody drugs to treat cancer and autoimmune
disorders. In addition, HiFiBiO Therapeutics aspires to address unmet
medical needs around the world through open-innovation partnerships with
industry and academia. The company features a strong global footprint
with cutting-edge laboratories on three continents in Cambridge, Mass.,
Paris, France, and Shanghai, China. For more information, please visit www.hifibio.com.

HiFiBiO Therapeutics, the HiFiBiO Therapeutics logo, CelliGO, and DIS
are trademarks of HiFiBiO Therapeutics, Inc. All other brands may be
trademarks of their respective holders.

Contacts

Media
Andrew Noble
Noble Communications
(415)
722-2129
[email protected]